CD44-DT regulates p21-dependent senescence via interacting with AR-PCNA complex, revealing a therapeutic vulnerability to chimeric ncRNA-mediated AR degradation in prostate cancer

Aberrant androgen receptor (AR) signaling driven by androgens plays a critical role in prostate cancer (PCa) progression. Interestingly, bipolar androgen therapy (BAT), a novel therapeutic strategy with cycles between near-castrate and supraphysiological androgen levels (SAL), suppresses PCa growth. SAL induces cellular senescence in various PCa models mediated by the AR, activation of AKT signaling and hypophosphorylation of pRb. Here, we show that SAL upregulates the lncRNA CD44-DT, the CD44 divergent transcript, in PCa cells linking CD44-DT to AR signaling. Knockdown and overexpression datasets suggest that CD44-DT supresses SAL-induced senescence as a negative feed-back loop. Transcriptome, ATAC-seq, and ChIP-seq analyses of PCa cells reveal that AR is recruited to the first intron of CD44 gene locus. Transcriptome analyses of the knockdown suggests that members of AP-1 family act in concert with AR as an upstream activator of CD44-DT. Accordingly, inhibition of the AP-1 complex by a small molecule inhibitor results in downregulation of CD44-DT expression, enhanced SAL-induced senescence and reduced proliferation. Mechanistically, CD44-DT physically interacts with PCNA and AR. This interaction facilitates p21 tumor suppressor degradation, permits cyclin-CDK activation, retinoblastoma (Rb) hyperphosphorylation activation of the AKT-p70S6K pathway. These findings suggest that CD44-DT is part of AR signaling and acts as a novel onco-lncRNA that is upregulated by AR. To validate the role of AR, we engineered a chimeric ncRNA capable degrading the AR as a novel type of RNA-PROTAC. Accordingly, this RNA-based AR-degrader downregulates CD44-DT confirming AR regulation of CD44-DT. Interestingly, the RNA-PROTAC potently induces apoptosis. Thus, the data suggest that CD44-DT is a novel direct AR target gene that modulates PCNA and p21 protein stability identifying a novel negative feed-back loop at the crossroad between proliferation and senescence indicating CD44-DT as a potential therapeutic target for PCa.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.17.767372
Primary Topic
Prostate Cancer Treatment and Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

CD44-DT regulates p21-dependent senescence via interacting with AR-PCNA complex, revealing a therapeutic vulnerability to chimeric ncRNA-mediated AR degradation in prostate cancer

Norman Rahnis, Forough Hakiminia, Julia Kallenbach, Katrin Schindler et al.
bioRxiv (Cold Spring Harbor Laboratory)
Prostate Cancer Treatment and Research
preprint

CD44-DT regulates p21-dependent senescence via interacting with AR-PCNA complex, revealing a therapeutic vulnerability to chimeric ncRNA-mediated AR degradation in prostate cancer

Norman Rahnis, Forough Hakiminia, Julia Kallenbach, Katrin Schindler, Aria Baniahmad, Golnaz Atri Roozbahani, Malek Hossein Asadi
preprint en

Abstract

Aberrant androgen receptor (AR) signaling driven by androgens plays a critical role in prostate cancer (PCa) progression. Interestingly, bipolar androgen therapy (BAT), a novel therapeutic strategy with cycles between near-castrate and supraphysiological androgen levels (SAL), suppresses PCa growth. SAL induces cellular senescence in various PCa models mediated by the AR, activation of AKT signaling and hypophosphorylation of pRb. Here, we show that SAL upregulates the lncRNA CD44-DT, the CD44 divergent transcript, in PCa cells linking CD44-DT to AR signaling. Knockdown and overexpression datasets suggest that CD44-DT supresses SAL-induced senescence as a negative feed-back loop. Transcriptome, ATAC-seq, and ChIP-seq analyses of PCa cells reveal that AR is recruited to the first intron of CD44 gene locus. Transcriptome analyses of the knockdown suggests that members of AP-1 family act in concert with AR as an upstream activator of CD44-DT. Accordingly, inhibition of the AP-1 complex by a small molecule inhibitor results in downregulation of CD44-DT expression, enhanced SAL-induced senescence and reduced proliferation. Mechanistically, CD44-DT physically interacts with PCNA and AR. This interaction facilitates p21 tumor suppressor degradation, permits cyclin-CDK activation, retinoblastoma (Rb) hyperphosphorylation activation of the AKT-p70S6K pathway. These findings suggest that CD44-DT is part of AR signaling and acts as a novel onco-lncRNA that is upregulated by AR. To validate the role of AR, we engineered a chimeric ncRNA capable degrading the AR as a novel type of RNA-PROTAC. Accordingly, this RNA-based AR-degrader downregulates CD44-DT confirming AR regulation of CD44-DT. Interestingly, the RNA-PROTAC potently induces apoptosis. Thus, the data suggest that CD44-DT is a novel direct AR target gene that modulates PCNA and p21 protein stability identifying a novel negative feed-back loop at the crossroad between proliferation and senescence indicating CD44-DT as a potential therapeutic target for PCa.

bioRxiv (Cold Spring Harbor Laboratory)
Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE), Jena University Hospital (DE), DNA Diagnostic (Denmark) (DK)
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon